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Due to its central role in several processes associated with 
inflammation,1 the activation of Nrf2 (Nuclear factor (erythroid-
derived 2)-like 2) has become an attractive target for the 
development of therapeutic interventions.2 As a transcription 
factor, Nrf2 is involved in the activation of various pathways that 
are associated with cellular stress. The binding of Nrf2 to DNA 
leads to the production of proteins such as heme-oxygenase 1 (HO-
1)3 and NAD(P)H:quinone oxidoreductase 1 (NQO1)4 that play a 
protective role in the cell. Nrf2 is closely controlled by the 
presence of the protein Kelch-like ECH-associated protein 1 
(Keap1), which binds to it and induces ubiquitination and 
proteasome mediated degradation.5 This then leads to the 
observation that the inhibition of the Nrf2/Keap1 interaction, a 
protein-protein interaction (PPI), could lead to the activation of 
Nrf2, which could have a subsequent beneficial effect in acute and 
chronic conditions involving inflammation.      
In the clinic, Nrf2 activation is involved in the use of dimethyl 
fumarate to treat multiple sclerosis6 and clinical evaluation of 
bardoxolone in the treatment of chronic kidney disease is still 
continuing.7     Both of these compounds are likely to interact in a 
covalent fashion with Keap1.  
Efforts to target the Nrf2/Keap1 interaction that do not involve 
covalent modification have begun to gather pace over the last few 
years. The interaction involves two binding sites on Keap1 – a high 
affinity ETGE sequence and a low affinity DLG site.8 The ETGE 
site involves a loop from Nrf2 and studies by Hannink and co-
workers9 showed that a 14mer sequence LQLDEETGEFLPIQ 
could bind to the site with high affinity. We later showed that 
conjugation of this sequence to a cell penetrating TAT-peptide led 
to a molecule with the ability to activate an anti-inflammatory 
response in THP1 human monocytic cells.10 As well as other 
peptide based approaches,11-14 there have been several small 
molecules developed to target the Nrf2/Keap1 interaction, based 
upon library screening, structure based ligand design or click 
chemistry.15-18 
As the peptide that binds to the ETGE sequence forms a loop 
or turn structure (Fig 1A), one intriguing approach to generating 
high affinity peptidic structures is to generate cyclic peptides.19 
Such structures can often have advantages of stability, affinity and 
cellular uptake over linear peptides. One of the simplest 
approaches to generating a cyclic peptide is to generate a disulfide 
bridge and indeed, a recent publication has demonstrated that 
cyclic peptides based upon the Nrf2 binding motif have a high 
affinity for Keap1.20 This has prompted us to disclose our own 
investigations of cyclic peptides targeting the Nrf2/Keap1 
interaction. Herein, we show that our disulfide bridged compounds 
had high binding affinity to Keap1 compared with the linear 
structures but were inactive in cells. Incorporation of a staple 
through reaction with hexafluorobenzene generated the first 
perfluoroarene stapled peptides21.22 targeting the Nrf2/Keap1 
interaction and gave a cyclic peptide that was amongst the highest 
affinity binding peptides that we have studied, however stapling in 
this way did not generate intracellularly active molecules. 
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The Nrf2/Keap1 interaction is a target in the development of new therapeutic agents, where 
inhibition of the interaction activates Nrf2 and leads to the generation of downstream anti-
inflammatory effects. Peptides that mimic the β-turn in the Keap1 active site and are constrained 
by a disulfide bridge have high affinity for Keap1 but no intracellular activity. The introduction 
of a perfluoroalkyl- bridging group to constrain the peptides, coupled with glutamic acid to proline 
replacement leads to a new peptide with a Ki of 6.1 nM for the Nrf2/Keap1 binding interaction, 
although this does not translate into intracellular activity.         
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Figure 1 A. Interactions between the Nrf2 DEETGE (in red) and the Keap1 binding site, showing the turn structure adopted by the Nrf2 in the binding site. B. 
The peptide sequences used for the first part of this study. C. Example of the route to synthesis of the peptides, in this case H2N-Ds8 (2) See supporting 
information for a full description. HBTU = O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate, HOBt = N-Hydroxybenzotriazole, DIPEA = 
N,N-diisopropylethylamine, DMF = N, N-Dimethylformamide, TFA = Trifluoroacetic acid, EDT = 1,2-ethanedithiol, TIPS = Triisopropylsilane. 
   
 
         
In order to study the effects of cyclising the peptide through a 
disulfide bridge, we chose three sequences to flank with cysteines 
– the core DEETGE motif (CDEETGEC, Ds8), a longer motif with 
the amino acids generating LDEETGEF (CLDEETGEFC, Ds10) 
and a truncated version containing only the central ETGE 
(CETGEC, Ds6) (Fig 1B). The linear sequences were generated on 
Rink amide resin23 to give the C-terminal amide compounds and 
were acetylated on the N-terminus. To assess the appropriate 
nature of these end groups, Ds8 was also made without the N-
terminal acetylation (H2N-Ds8) (Fig 1C) and on 2-chlorotrityl 
resin to generate the free acid at the C-terminus (Ds8-OH). 
Oxidation of the peptides with I2/AcOH formed the cyclic 
peptides. All compounds were purified by HPLC and their 
identities were confirmed by MALDI-TOF MS (See Supporting 
Information for full details). 
The ability of the peptides to inhibit the Nrf2/Keap1 interaction 
was initially assessed by a fluorescence polarisation assay.24 The 
14mer peptide LQLDEETGEFLPIQ was labelled at the N-
terminus via reaction with fluorescein isothiocyanate in DMSO 
with triethylamine as base. The product (F-14) was purified by 
preparative HPLC and identified through MALDI-TOF mass 
spectrometry. The assay was optimised to utilise the Keap1 Kelch 
domain (352-609) at a 30 nM final concentration and 5 nM F-14. 
A sample inhibition curve (for Ds8) in shown in Figure 2 and the 
resulting values for the disulfide peptides in Table 1. 
  
Figure 2. FP inhibition by Ds8 peptide. n = 3, 30 nM Keap1, 5 nM F14 
 
 Peptide Ki (nM) 95% CI (nM) R2 
1 Ds8 95 73.2-123.3 0.9899 
6 Ln8 1300 1100-1500 0.9942 
4 Ds6 151500 88800-
258700 
0.9522 
7 Ln6 280400 116200-
676200 
0.9246 
5 Ds10 47.9 33.1-69.2 0.9807 
8 Ln10 176.9 135.6-230.6 0.9900 
3 Ds8-OH 47.7 35.5-64.1 0.9875 
2 H2N-Ds8 274.9 182.6-413.8 0.9770 
 
Table 1. Ki values for Fp inhibition by cyclic disulfides, n = 
3, 30 nM Keap1, 5 nM F-14. CI – confidence intervals. For 
calculations see supporting information. Ln = linear 
 
Clearly, cyclisation of the Ds8 peptide had a significant effect 
on the binding affinity – with >10 fold increase in Ki for Ds8 over 
the linear peptide and over 25 fold for Ds8-OH. Ds10 also shows 
a modest increase over the linear peptide, maintaining low nM 
activity. It is also clear that the Ds6 peptide is too short to maintain 
good binding affinity. 
These compounds were then assessed for the ability to activate 
HO-1 expression in THP1 cells using RT-PCR and in comparison 
with TAT14. None of the compounds exerted a biological effect at 
any of the time points investigated. This is strongly suggestive 
that, even in the cyclic form, these compounds are either not 
entering the cells, or are being reduced to a linear form and 
metabolised during uptake. 
“Peptide stapling” involves the constraining of peptides in 
particular conformations through the incorporation of novel linker 
groups. Most of the focus of this approach has been on the 
introduction of groups that stabilise an -helix in systems 
targeting, for example, the p53/MDM2 protein-protein 
interaction.25 Olefin metathesis reactions have been popular in this 
context and there has been some discussion as to whether groups 
that are incorporated into a peptide also facilitate cellular uptake.26 
One of the drawbacks of many of these methods is that they 
involve the incorporation of non-natural amino acids, sometimes 
generated through multistep synthetic routes, so that more 
synthetically tractable and simple approaches are highly desirable. 
One such simple approach was recently described by Pentelute 
and co-workers21 and involves macrocyclisation through the 
reaction of cysteines with hexafluorobenzene or 
decafluorobiphenyl under mild conditions. This chemistry was 
successfully applied to the generation of relatively stable -helical 
Her-2-affibodies and was also shown to increase the penetration of 
peptides through the blood-brain barrier.22 As such, this 
represented a potential approach to generate constrained -turn 
type cyclic peptides for the Nrf2/Keap1 interaction under mild 
conditions.   
In order to generate the perfluoroaryl peptide macrocycles, 
Ln6, Ln8 and Ln10 were resynthesised, cleaved from the resin and 
purified. They were then treated with a large excess (25 
equivalents) of a solution of hexafluorobenzene (50 mM) and 
TRIS-base (25 mM) in DMF at room temperature for 18 h 
(Scheme 1). Following purification both Ln6 and Ln8 starting 
materials generated the target compounds Ar6 (9) and Ar8 (10), 
whereas, somewhat surprisingly, the Ln10 only gave the disulfide 
bridged analogue Ds10. Two further peptides were also 
synthesised. Wells and co-workers12 have previously shown that 
the incorporation of a proline in place of glutamic acid in the 
sequence DEETGE (i.e. DPETGE) helps to induce the formation 
of a -turn, while the glutamic acid replaced (equivalent to Glu78 
in the human Nrf2 sequence, see Fig 1A) does not make a 
significant contribution to binding interactions. As such, we also 
synthesised the peptides CDPETGEC (Ar8P, 11) and 
CLDPETGEFC (Ar10P, 12) equivalent to Ln8 and Ln10 
respectively. When subjected to reaction with hexafluorobenzene 
under similar conditions, these two compounds generated the 
perfluoroaryl peptide macrocycles Ar8P and Ar10P. 
 
Scheme 1. Synthesis of the perfluoroarene stapled peptides. 
             
 Peptide Ki (nM) 95% CI (nM) R2 
9 Ar6 - - - 
10 Ar8 1400 1100-1700 0.9914 
11 Ar8P 6.1 4.4-8,5 0.9827 
12 Ar10P 61.9 46.1-83.0 0.9861 
Table 2. Ki values for Fp inhibition by perfluoroarene 
compounds, n = 3, 30 nM Keap1, 5 nM F-14. CI – confidence 
intervals. For calculations see supporting information.  
 
The Ar6 peptide showed no binding to Keap1 at concentrations 
that were tested in this assay. Somewhat disappointingly, the 
binding affinity for Ar8, in which the disulfide bridge has been 
crosslinked by the perfluoroaryl group, is almost 15-fold lower 
than the value for the disulfide compound and is more similar to 
the linear peptide (see Table 1). This suggests that the increased 
size of the cyclic peptide induced by the introduction of the aryl 
group means that the “fit” of the turn structure within the binding 
site is no longer appropriate. Introduction of the proline residue in 
place of a Glu in compound 11 (Ar8P) leads to a molecule that is 
amongst the most potent that we have seen in this assay, with a Ki 
of 6.1 nM, this time 15-fold higher than Ds8. The less rigid, longer 
cyclic peptide 12 (Ar10P) is almost equipotent with 5. 
Although it has been reported that the introduction of the 
perfluoroaryl linker can lead to an increase in cellular uptake, none 
of the compounds had measurable activity in THP-1 cells when 
studied by RT-PCR for their effects on HO-1 message production, 
or on HO-1 protein expression studied by western blot analysis, 
when cells were stimulated by LPS. HO-1 is a downstream product 
of activation of Nrf2 as a transcription factor.3, 10 This is 
presumably an effect of restricted access for these molecules into 
the cell and to their site of action. All compounds in the study were 
also examined for their anti-proliferative activity in THP-1 cells 
and no effect was observed. 
 In summary, peptides were designed to bind to the Keap1 
protein and inhibit its interaction with Nrf2. These peptides 
mimicked the -turn of the Nrf2 sequence containing DEEGTE. 
While constraining the peptides with a disulfide bridge gave high 
affinity binders and confirmed the result seen by Jiang and co-
workers,20 these compounds did not have intracellular activity. As 
this could be because the compounds either do not penetrate the 
cell membrane or because they are reduced in the cellular 
environment, we incorporated a perfluoroalkyl bridge using 
hexafluorobenzene to both stabilise the cyclic structure and also to 
introduce a group that had been shown to enhance cell penetration. 
Both compounds Ar8P and Ar10P had a high affinity for the 
Keap1 binding site, with a Ki for Ar8P of 6.1 nM being the lowest 
value that we have observed using peptides and small molecules 
in an Fp assay. Unfortunately, this high affinity did not translate 
into cellular activity and research is continuing to generate 
analogues of Ar8P with similar binding affinity but enhanced 
cellular penetration. 
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